Sökning: id:"swepub:oai:DiVA.org:uu-430517" >
Prevalence of CYP2C...
Prevalence of CYP2C8*2 and *3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment
-
- Habtemikael, Lidia (författare)
- Uppsala universitet,Internationell mödra- och barnhälsovård (IMCH)
-
- Russom, Mulugeta (författare)
- Minist Hlth, Natl Med & Food Adm, Asmera, Eritrea
-
- Bahta, Iyassu (författare)
- Minist Hlth, Natl Med & Food Adm, Asmera, Eritrea
-
visa fler...
-
- Mihreteab, Selam (författare)
- Minist Hlth, Natl Malaria Control Programme, Asmera, Eritrea
-
- Berhane, Araia (författare)
- Minist Hlth, Communicable Dis Control Div, Asmera, Eritrea
-
- Mårtensson, Andreas, 1963- (författare)
- Uppsala universitet,Internationell barnhälsa och nutrition
-
- Gil, Jose Pedro (författare)
- Karolinska Institutet,Uppsala universitet,Internationell barnhälsa och nutrition,Karolinska Inst, Dept Microbiol & Tumour Cell Biol, Stockholm, Sweden; Univ Lisbon, Fac Sci, Biosyst & Integrat Sci Inst, Lisbon, Portugal
-
visa färre...
-
(creator_code:org_t)
- 2020
- 2020
- Engelska.
-
Ingår i: Pharmacogenomics and Personalized Medicine. - 1178-7066. ; 13, s. 571-575
- Relaterad länk:
-
https://doi.org/10.2...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: In Eritrea, artesunate–amodiaquine is the first-line treatment against uncomplicated malaria. Amodiaquine, which is mainly bio-transformed by CYP2C8, is known to be associated with adverse events of different severity. Extrapyramidal events are among the less common but have been reported with non-negligible frequency in Eritrea. This study was conducted to investigate the allele frequencies of CYP2C8*2 and *3, both associated with decreased amodiaquine metabolism, among the Eritrean population.Methods: During September–November 2018, dried blood samples from 380 participants and 17 patients who previously had experienced extrapyramidal symptoms following treatment of artesunate–amodiaquine were collected and PCR-RFLP genotyped for CYP2C8*2 and *3.Results: The allele frequencies of CYP2C8*2 and *3 were determined as 5.9% (95% CI: 4.4– 7.8) and 4.6% (95% CI: 3.2– 6.3), respectively. Four out of the 17 patients with extrapyramidal reactions showed to be carriers of the alleles.Conclusion: CYP2C8*2 and *3 frequencies among Eritreans were found to be intermediate between the documented for Caucasian and African populations. These findings, along with the alleles not being decisive for the occurrence of extrapyramidal events, might be of importance regarding the amodiaquine-containing malaria treatment in Eritrea. Furthermore, it suggests a significant proportion of slow amodiaquine metabolizers in the Sahel region, information of potential interest in the context of amodiaquine-involving seasonal malaria chemoprevention.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- malaria
- uncomplicated
- artesunate/amodiaquine
- CYP2C8
- slow metabolizers
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas